Christopher Garabedian is the President and CEO of Sarepta Therapeutics, a company focused on developing therapies for rare diseases like Duchenne Muscular Dystrophy (DMD). He took over as CEO in January 2011 after being appointed to the board in 2010....

Christopher Garabedian is the President and CEO of Sarepta Therapeutics, a company focused on developing therapies for rare diseases like Duchenne Muscular Dystrophy (DMD). He took over as CEO in January 2011 after being appointed to the board in 2010. Garabedian has an MBA from Harvard Business School, which shows he's got a solid business foundation. Before joining Sarepta, he played key roles at Celgene and Gilead Sciences, giving him a strong background in the pharmaceutical industry. His leadership style is hands-on. He emphasizes aligning the company’s goals with long-term shareholder interests, indicating that he thinks strategically about the future. During his time at Sarepta, he earned a total compensation of about $979,000 in 2016, with a significant cash bonus for achieving corporate goals. Garabedian demonstrated confidence in the company by holding substantial stock options, which highlights his belief in Sarepta's mission. His track record includes guiding Sarepta through critical trial phases, especially with the drug eteplirsen, which was pivotal for DMD patients. Overall, he has been a significant figure in pushing the biotechnology field forward, especially in developing treatments for genetic disorders.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Sarepta Therapeutics, Inc. CEOs

S

Christopher Garabedian

Ex-CEO of Sarepta Therapeutics, Inc.

Education

MBA from Harvard Business School

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

March 15, 1968 - 57 years ago

CEO of Sarepta Therapeutics, Inc. for

4 years 10 months (Jul 2011 - Jun 2016)

Previous Experience

President of Sarepta Therapeutics, Inc.

Rivals

Competitors/colleagues of Christopher Garabedian

Holdings

See how much did Christopher Garabedian make over time.

Christopher Garabedian has shown a strong financial commitment to Sarepta Therapeutics. His insider trading activity reflects significant stock holdings with values fluctuating dramatically. For instance, in December 2019, his holdings peaked at approximately $48.54 million. However, fluctuations occurred as values...

Christopher Garabedian has shown a strong financial commitment to Sarepta Therapeutics. His insider trading activity reflects significant stock holdings with values fluctuating dramatically. For instance, in December 2019, his holdings peaked at approximately $48.54 million. However, fluctuations occurred as values dipped to around $31.95 million in September 2019. In 2020, the value of his holdings saw considerable growth, hitting a high of $66.84 million by December. Over the years, his confidence in Sarepta has been apparent in the increasing value of his holdings, which directly ties to the company's drug development successes and FDA approvals. This trend illustrates his alignment with the company's performance, showcasing his commitment to its long-term vision and his stake in its accomplishments.

Insider Trading

See recent insider trades of Christopher Garabedian.

SRPT

$9.45K

SRPT at $11.82/share

Feb 27, 2015

Purchase

Compensation History

See how much did Christopher Garabedian make over time.

In terms of compensation, Christopher Garabedian's pay package is reflective of his leadership role at Sarepta Therapeutics. When he joined in 2011, his base salary started at $490,000. By 2016, his total compensation increased to approximately $979,000, driven mostly by performance bonuses tied to corporate goals. His salary and bonus structure emphasized performance, rewarding him for achieving milestones, such as advancing drug development for DMD. Garabedian's compensation was also designed to align with market standards for similar roles within biopharmaceutical firms, ensuring he is compensated competitively. His pay includes cash bonuses based on corporate targets, signifying a strong connection between his financial rewards and the company's success, which is crucial in the high-stakes world of biotech innovation.

Year

2016

Total Compensation

$979.00K

Salary

$550.00K

Board Justification

The compensation committee aimed to align executive compensation with company performance and market competitiveness, focusing on attracting and retaining top talent in a challenging regulatory environment.

Bonus

$429.00K

Board Justification

Cash bonus based on achievement of corporate goals, targeted at 65% of base salary after his appointment as CEO in September 2016.

Other

$0.00

Board Justification

No additional compensation was reported for the CEO in 2016.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2016 for the CEO.

Performance Metrics

Performance metrics included securing FDA accelerated approval for EXONDYS 51 and achieving corporate goals related to the commercialization of the product.

Other Sarepta Therapeutics, Inc. CEOs

Here are other CEOs of Sarepta Therapeutics, Inc.

J. David Boyle II

Ex-CEO of Sarepta Therapeutics, Inc.

April 2010 - July 2011

Doug Ingram

CEO of Sarepta Therapeutics, Inc.

June 2016 - Present